Article Text

Download PDFPDF
Glycoprotein Ia C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up
  1. A M Leone,
  2. V De Stefano,
  3. F Burzotta,
  4. P Chiusolo*,
  5. I Casorelli*,
  6. K Paciaroni*,
  7. E Rossi*,
  8. A Sciahbasi,
  9. L Testa,
  10. G Leone*,
  11. F Crea,
  12. F Andreotti
  1. Institute of Cardiology and
  1. Correspondence to:
    Dr Antonio Maria Leone
    Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Despite aggressive control of modifiable risk factors, recurrent acute coronary syndromes are still common, and the underlying mechanisms largely elusive. Glycoprotein (Gp) Ia/IIa is one of several collagen receptors involved in platelet adhesion.1 A C807T gene variant of GpIa is related to Gp Ia/IIa receptor density on the platelet surface,2 with the density proportionate to the number of T alleles.2 Previous case-control studies in white subjects have associated this variant with acute ischaemic heart disease.3 As it is not known whether the 807T allele may also predict recurrent acute coronary syndromes, this was investigated in 117 survivors of a first acute coronary event; patients were followed for up to five years.


Between 1996 and 1998 we enrolled 195 patients below the age of 65 years; these patients were discharged from our coronary care unit with a diagnosis of acute myocardial infarction (MI), according to World Health Organization criteria, (MI, n  =  141) or severe Braunwald class IIIB unstable angina (UA, n  =  54) at first presentation of disease. After informed consent for genetic analyses, a final number of 117 patients (79 MI, 38 UA) accepted follow up assessment which took place at six months, two years, and five years. Clinical evaluation was blinded to the results of genotyping. Major cardiovascular risk factors, angiographic extent of disease, and left ventricular ejection fraction (LVEF) were assessed at enrolment. Antiplatelet drugs during follow up consisted of aspirin or ticlopidine if aspirin was contraindicated. Following percutaneous coronary interventions, aspirin and ticlopidine were both prescribed for four weeks. Gp IIb/IIIa inhibitors were not administered.

The primary end point was the composite of fatal and …

View Full Text


  • * Institute of Haematology, Catholic University, Rome, Italy